Immix Biopharma, Inc.
NASDAQ:IMMX
2.17 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | Immix Biopharma, Inc. |
| Symbool | IMMX |
| Munteenheid | USD |
| Prijs | 2.17 |
| Beurswaarde | 62,570,019 |
| Dividendpercentage | 0% |
| 52-weken bereik | 1.26 - 3.2 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. |
| Website | https://www.immixbio.com |
An error occurred while fetching data.
Over Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)



